Published on May 10, 2012 at 12:16 AM
Inovio's new skin electroporation technology significantly enhanced delivery of small interfering RNA (siRNA) molecules to skin and also demonstrated gene knockdown (silencing) in animal studies.
Inovio's SynCon® therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, associated with head & neck cancers and genital warts, induced strong antigen-specific CD8+ T cells in mice, mirroring robust T-cell responses induced by VGX-3100 in earlier mice studies.
Corporate & Business Development
Inovio received a patent covering its synthetic consensus influenza H1 antigen, which relates to our H1N1 influenza constructs and INO-3510 universal influenza vaccine.
Inovio was awarded a U.S. Department of Defense Small Business Innovation Research Grant to advance a low-cost, non-invasive surface electroporation delivery device and test its utility in combination with Inovio synthetic vaccines against viruses with bioterrorism potential.
Niranjan Y. Sardesai, Ph.D., was promoted to Chief Operating Officer and is now responsible for corporate and business development in addition to overseeing research and development.
Dr. Anthony Ford-Hutchinson, recently retired from his role as Senior Vice President, Vaccines Research and Development at Merck, joined Inovio's Scientific Advisory Board.
Dr. Adel Mahmoud was appointed to Inovio's Board of Directors. He is a professor at Princeton University, was President, Merck Vaccines, from 1999 to 2005, and also served as Merck's Chief Medical Advisor for Vaccines and Infectious Diseases.
Inovio has an expanding dialog with vaccine and biotechnology companies as well as non-governmental and government agencies with the goal of securing non-dilutive funding for its vaccine programs and potentially new collaborations and partnerships to advance the development and commercialization of its SynCon® vaccine platform and specific SynCon vaccines.
SOURCE Inovio Pharmaceuticals, Inc.